@entity5337 mutation triggering four major complications to standard dose cisplatin-chemotherapy for XXXX : a case report.

@entity1 @entity5337 @entity558 @entity55 @entity5 @entity16 @entity3794 @entity49 @entity1188 @entity358 @entity4797 @entity715
BACKGROUND: Major life-threatening complications secondary to cisplatin-based chemotherapy are rare in @entity1 with @entity5 ( @entity5 ). The incidence of complications increases with dosage of chemotherapy and with a variety of @entity1 -related as well as disease-related conditions. We here report the first case of @entity5 experiencing as many as four major complications most of which can be explained by the conjunction of several predispositions. CASE PRESENTATION: A 48  year old @entity1 with @entity4797 and bulky retroperitoneal and mediastinal metastases underwent cisplatin based chemotherapy. During the third cycle of chemotherapy, he developed @entity715 of the central venous port device, subtotal @entity1188 , and Bleomycin induced @entity55 (BIP). Three months after completion of therapy, he was struck by @entity1188 . Genetic testing then revealed heterozygote mutation of @entity5337 ( @entity5337 ). He received full-dose warfarin anticoagulation treatment and steroid treatment for BIP. 18  months thereafter, the @entity1 is still disease-free, oncologically. @entity16 have disappeared, but @entity358 persists with a vital capacity of 50%. CONCLUSION: The unique co-incidence of four major complications occurring in this @entity1 were obviously triggered by the genetically determined predisposition of the @entity1 to @entity715 events ( @entity5337 ). Additionally, several @entity1 -related and disease-related conditions contributed to the unique pattern of complications, i.e. (1) the slightly advanced age (48  years), (2) the @entity558 caused by the disease of @entity5 , (3) the central venous port device, (4) retroperitoneal bulky metastasis, and (5) cisplatin chemotherapy. Whether or not @entity5337 contributed to the @entity3794 as well, remains elusive. Practically, in the case of one major vascular complication during cisplatin chemotherapy at standard dose, genetic testing for hereditary @entity49 should be considered. Thus, precautions for preventing further complications could be initiated.
